Rules balance access to promising new therapies against the need to protect patient safety.
A high intake of dietary polyamines, which are commonly found in orange juice, corn, red meat, peas, and nuts, has been linked to the size and grade of colorectal adenomas found on screening colonoscopy.
Confusion over important prognostic indicator may lead to unnecessary treatment.
A novel IGF-receptor inhibitor stabilized disease in a majority of pancreatic cancer patients, according to a report at the 2010 GI Cancers Symposium.
Screening is the key to protecting those at risk for pancreatic cancer, according to presenters at the 2010 Gastrointestinal Cancers Symposium.
A primer on managing the chemorefractory patient from Eric Van Cutsem, MD, PhD.
The RIBBON-2 trial met its primary endpoint of prolonged progression-free survival.
Higher doses of the estrogen-receptor antagonist fulvestrant (Faslodex) may increase treatment benefit without increasing toxicity, according to results from the international, randomized, double-blind phase III CONFIRM trial.
The seminal IPASS study by Tony Mok, MD, and colleagues demonstrated moderate efficacy for gefitinib (Iressa) in advanced non–small–cell lung cancer patients, most notably in patients with predictive factors, including adenocarcinoma histology, no history of smoking, and Asian ethnicity.
The RANK ligand inhibitor was better tolerated and more convenient for patients with skeletal metastasis.